Therapeutics for COVID-19
SS Toussi, JL Hammond, BS Gerstenberger… - Nature …, 2023 - nature.com
Vaccines and monoclonal antibody treatments to prevent severe coronavirus disease 2019
(COVID-19) illness were available within a year of the pandemic being declared but there …
(COVID-19) illness were available within a year of the pandemic being declared but there …
Antibodies to combat viral infections: development strategies and progress
G Pantaleo, B Correia, C Fenwick, VS Joo… - Nature Reviews Drug …, 2022 - nature.com
Monoclonal antibodies (mAbs) are appealing as potential therapeutics and prophylactics for
viral infections owing to characteristics such as their high specificity and their ability to …
viral infections owing to characteristics such as their high specificity and their ability to …
Multivalent designed proteins neutralize SARS-CoV-2 variants of concern and confer protection against infection in mice
New variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to
arise and prolong the coronavirus disease 2019 (COVID-19) pandemic. Here, we used a …
arise and prolong the coronavirus disease 2019 (COVID-19) pandemic. Here, we used a …
SARS-CoV-2 antiviral therapy
The development of effective antiviral therapy for COVID-19 is critical for those awaiting
vaccination, as well as for those who do not respond robustly to vaccination. This review …
vaccination, as well as for those who do not respond robustly to vaccination. This review …
The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants
S Rothenberger, DL Hurdiss, M Walser… - Nature …, 2022 - nature.com
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
with potential resistance to existing drugs emphasizes the need for new therapeutic …
with potential resistance to existing drugs emphasizes the need for new therapeutic …
Mutation-induced changes in the receptor-binding interface of the SARS-CoV-2 Delta variant B. 1.617. 2 and implications for immune evasion
Following the initial surges of the Alpha (B. 1.1. 7) and the Beta (B. 1.351) variants, a more
infectious Delta variant (B. 1.617. 2) is now surging, further deepening the health crises …
infectious Delta variant (B. 1.617. 2) is now surging, further deepening the health crises …
[HTML][HTML] Coronavirus entry: how we arrived at SARS-CoV-2
Because of the COVID-19 pandemic, the novel coronavirus SARS-CoV-2 has risen to shape
scientific research during 2020, with its spike (S) protein being a predominant focus. The S …
scientific research during 2020, with its spike (S) protein being a predominant focus. The S …
A potent and broad neutralization of SARS-CoV-2 variants of concern by DARPins
We report the engineering and selection of two synthetic proteins—FSR16m and FSR22—
for the possible treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV …
for the possible treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV …
Treatments for COVID-19: Lessons from 2020 and new therapeutic options
F Salasc, T Lahlali, E Laurent, M Rosa-Calatrava… - Current Opinion in …, 2022 - Elsevier
To face the COVID-19 pandemic, prophylactic vaccines have been developed in record
time, but vaccine coverage is still limited, accessibility is not equitable worldwide, and the …
time, but vaccine coverage is still limited, accessibility is not equitable worldwide, and the …
COVID-19, Influenza and RSV: Surveillance-informed prevention and treatment–Meeting report from an isirv-WHO virtual conference
JL McKimm-Breschkin, AJ Hay, B Cao, RJ Cox… - Antiviral Research, 2022 - Elsevier
Abstract The International Society for Influenza and other Respiratory Virus Diseases (isirv)
and the WHO held a joint virtual conference from 19th-21st October 2021. While there was a …
and the WHO held a joint virtual conference from 19th-21st October 2021. While there was a …